Data-driven stock analysis, valuation deep dives, and financial forensics. Every article backed by the numbers.
Newmont at 16x earnings with gold above $2,300. Freeport with Grasberg ramping into a copper deficit. Vale at 6x earnings yielding 10% FCF. The sector is mispriced.
Freed from the conglomerate, GE Aerospace has tripled in value. With 70% service revenue at 35-40% margins and a 40-year installed base, the premium is earned.
Three quarters of flat volume growth, private label pressure at 25-30% penetration, and a 28x multiple pricing in growth that isn't materialising.
Seven consecutive earnings beats, 41% operating margins, and the largest AI infrastructure buildout in big tech. The valuation does not reflect any of it.
Exxon trades at a $265 billion premium to Chevron. The Pioneer acquisition, Permian dominance, and superior capital allocation justify every dollar of it.
Streaming just turned profitable. Parks generate $8B in operating income. ESPN is getting its own platform. The IP library is permanent. The stock trades at a discount to the S&P.
The Western minerals alliance is a decade-long tailwind for BHP's copper portfolio. At 14.6x forward earnings, the stock underprices the coming supply deficit.
The pivot from process node competition to custom silicon design plays to Intel's actual strengths. But execution risk remains extreme.
Membership fee revenue funds 100% of operating profit. Renewal rates top 92%. The data reveals a subscription business hiding inside a warehouse retailer.
Trailing P/E is the wrong frame for a company generating $96.7 billion in free cash flow.
Oppenheimer calls the concerns 'overblown.' At 30x forward revenue with 35% growth and 78% gross margins, the edge network moat is being underpriced.
The defence floor holds, but the commercial recovery timeline just extended by 12-18 months. The balance sheet can't afford another setback.
A sum-of-parts analysis shows SoFi's technology platform alone could justify the current market cap. The lending business and 10 million members come free.
Consensus sees a car company in decline. The data points to an energy and autonomy inflection the market has completely ignored.
The shift from injectable to oral delivery could expand the addressable GLP-1 market by 3-4x. Lilly's pharmacy partnerships make it a distribution play, not just a drug launch.